ArticleFrontiers in immunology2022
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Pooled it
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- B cell extracellular vesicles influence melanoma response to immune checkpoint therapy.Science advances · 2025Article
- Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial.Journal of pharmacy & bioallied sciences · 2025Article
- Toll-Like Receptors in the Immunotherapy Era: Dual-Edged Swords of Tumor Immunity and Clinical Translation.MedComm · 2025Review
- Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides.Dermatopathology (Basel, Switzerland) · 2025Review
- Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance.Cancer science · 2025Review
- The Multifaceted Role of the IL-2 Cytokine Family in Melanoma: Mechanisms, Therapeutic Implications, and Immune Modulation.Journal of immunology research · 2025Review
- Overcoming Resistance Mechanisms to Melanoma Immunotherapy.American journal of clinical dermatology · 2025Review
- Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients.Frontiers in immunology · 2025Article
- B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma.Journal for immunotherapy of cancer · 2024Article
- B cells as modulators of HPV+ oropharyngeal cancer in a preclinical model.Frontiers in oncology · 2023Article
- Immunometabolic reprogramming, another cancer hallmark.Frontiers in immunology · 2023Review
- [Melanoma-associated macrophages-from molecular signals to therapeutic application].Dermatologie (Heidelberg, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
Immunotherapies such as checkpoint blockade therapies are known to enhance anti-melanoma CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.